Home | Careers | Contact

Artielle ImmunoTherapeutics

Artielle ImmunoTherapeutics' technology is focused on a new proprietary class of molecules known as Recombinant T cell receptor Ligands (RTLs) that can be tailored to treat a wide range of autoimmune inflammatory diseases.  Artielle has developed a lead compound for the treatment of multiple sclerosis, called RTL1000, which has completed a Phase 1 clinical trial. In addition to multiple sclerosis, Artielle is conducting research on other autoimmune diseases to which its platform technology is also applicable, such as rheumatoid arthritis, celiac disease, uveitis, stroke, optic neuritis and type 1 diabetes.